Annual CFF
$6.42 M
+$4.79 M+293.57%
31 December 2023
Summary:
Lineage Cell Therapeutics annual cash flow from financing activities is currently $6.42 million, with the most recent change of +$4.79 million (+293.57%) on 31 December 2023. During the last 3 years, it has fallen by -$23.44 million (-78.49%). LCTX annual CFF is now -90.08% below its all-time high of $64.78 million, reached on 31 December 2015.LCTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$3000.00
-$108.00 K-102.86%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly cash flow from financing activities is currently -$3000.00, with the most recent change of -$108.00 thousand (-102.86%) on 30 September 2024. Over the past year, it has dropped by -$810.00 thousand (-100.37%). LCTX quarterly CFF is now -100.01% below its all-time high of $30.97 million, reached on 31 December 2014.LCTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$14.11 M
-$810.00 K-5.43%
30 September 2024
Summary:
Lineage Cell Therapeutics TTM cash flow from financing activities is currently $14.11 million, with the most recent change of -$810.00 thousand (-5.43%) on 30 September 2024. Over the past year, it has increased by +$7.55 million (+115.16%). LCTX TTM CFF is now -78.69% below its all-time high of $66.20 million, reached on 30 September 2015.LCTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +293.6% | -100.4% | +115.2% |
| 3 y3 years | -78.5% | -100.1% | -65.4% |
| 5 y5 years | +11.2% | -103.8% | +1870.7% |
LCTX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -82.6% | +293.6% | -100.0% | +76.9% | -65.4% | +1159.8% |
| 5 y | 5 years | -82.6% | +941.0% | -100.0% | +76.9% | -77.1% | >+9999.0% |
| alltime | all time | -90.1% | +3311.5% | -100.0% | +99.0% | -78.7% | +7155.0% |
Lineage Cell Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3000.00(-102.9%) | $14.11 M(-5.4%) |
| June 2024 | - | $105.00 K(-99.3%) | $14.92 M(-27.0%) |
| Mar 2024 | - | $14.02 M(<-9900.0%) | $20.44 M(+218.3%) |
| Dec 2023 | $6.42 M(+293.6%) | -$13.00 K(-101.6%) | $6.42 M(-2.1%) |
| Sept 2023 | - | $807.00 K(-85.7%) | $6.56 M(-2.3%) |
| June 2023 | - | $5.63 M(>+9900.0%) | $6.71 M(+499.6%) |
| Mar 2023 | - | $1000.00(-99.2%) | $1.12 M(-31.4%) |
| Dec 2022 | $1.63 M(-95.6%) | $122.00 K(-87.3%) | $1.63 M(-33.8%) |
| Sept 2022 | - | $964.00 K(+2821.2%) | $2.46 M(-52.8%) |
| June 2022 | - | $33.00 K(-93.6%) | $5.22 M(-68.3%) |
| Mar 2022 | - | $513.00 K(-46.2%) | $16.48 M(-55.4%) |
| Dec 2021 | $36.93 M(+23.7%) | $954.00 K(-74.3%) | $36.93 M(-9.5%) |
| Sept 2021 | - | $3.72 M(-67.1%) | $40.79 M(-33.8%) |
| June 2021 | - | $11.29 M(-46.1%) | $61.63 M(+21.2%) |
| Mar 2021 | - | $20.96 M(+335.5%) | $50.84 M(+70.2%) |
| Dec 2020 | $29.86 M(+4740.4%) | $4.81 M(-80.4%) | $29.86 M(+19.2%) |
| Sept 2020 | - | $24.56 M(+4782.3%) | $25.05 M(+4317.3%) |
| June 2020 | - | $503.00 K(-5130.0%) | $567.00 K(>+9900.0%) |
| Mar 2020 | - | -$10.00 K(+100.0%) | $1000.00(-99.8%) |
| Dec 2019 | $617.00 K(-89.3%) | -$5000.00(-106.3%) | $617.00 K(-13.8%) |
| Sept 2019 | - | $79.00 K(-225.4%) | $716.00 K(-8.4%) |
| June 2019 | - | -$63.00 K(-110.4%) | $782.00 K(-86.4%) |
| Mar 2019 | - | $606.00 K(+544.7%) | $5.75 M(-0.5%) |
| Dec 2018 | $5.77 M(-89.6%) | $94.00 K(-35.2%) | $5.77 M(-82.0%) |
| Sept 2018 | - | $145.00 K(-97.0%) | $32.06 M(-13.1%) |
| June 2018 | - | $4.90 M(+674.4%) | $36.91 M(-0.1%) |
| Mar 2018 | - | $633.00 K(-97.6%) | $36.93 M(-33.3%) |
| Dec 2017 | $55.39 M(+69.0%) | $26.38 M(+428.4%) | $55.39 M(+85.5%) |
| Sept 2017 | - | $4.99 M(+1.4%) | $29.86 M(-19.5%) |
| June 2017 | - | $4.92 M(-74.2%) | $37.07 M(-27.5%) |
| Mar 2017 | - | $19.10 M(+2165.4%) | $51.12 M(+55.9%) |
| Dec 2016 | $32.78 M(-49.4%) | $843.00 K(-93.1%) | $32.78 M(-46.7%) |
| Sept 2016 | - | $12.21 M(-35.6%) | $61.48 M(+1.7%) |
| June 2016 | - | $18.97 M(+2382.6%) | $60.43 M(+1.0%) |
| Mar 2016 | - | $764.00 K(-97.4%) | $59.85 M(-7.6%) |
| Dec 2015 | $64.78 M(+1.8%) | $29.54 M(+164.8%) | $64.78 M(-2.2%) |
| Sept 2015 | - | $11.16 M(-39.3%) | $66.20 M(+19.3%) |
| June 2015 | - | $18.39 M(+223.5%) | $55.50 M(-2.9%) |
| Mar 2015 | - | $5.68 M(-81.6%) | $57.18 M(-10.1%) |
| Dec 2014 | $63.62 M(+85.7%) | $30.97 M(+6662.7%) | $63.62 M(+52.3%) |
| Sept 2014 | - | $458.00 K(-97.7%) | $41.78 M(+1.1%) |
| June 2014 | - | $20.06 M(+65.4%) | $41.32 M(+24.2%) |
| Mar 2014 | - | $12.13 M(+32.9%) | $33.28 M(-2.9%) |
| Dec 2013 | $34.26 M(+1690.7%) | $9.13 M(<-9900.0%) | $34.26 M(+28.0%) |
| Sept 2013 | - | -$200.00(-100.0%) | $26.76 M(-1.0%) |
| June 2013 | - | $12.02 M(-8.3%) | $27.04 M(+79.9%) |
| Mar 2013 | - | $13.11 M(+706.1%) | $15.03 M(+685.3%) |
| Dec 2012 | $1.91 M(-50.5%) | $1.63 M(+498.5%) | $1.91 M(+566.0%) |
| Sept 2012 | - | $271.80 K(+1736.5%) | $287.30 K(-90.6%) |
| June 2012 | - | $14.80 K(>+9900.0%) | $3.05 M(-3.9%) |
| Mar 2012 | - | $0.00(-100.0%) | $3.17 M(-17.9%) |
| Dec 2011 | $3.86 M(-85.0%) | $700.00(-100.0%) | $3.86 M(-64.7%) |
| Sept 2011 | - | $3.03 M(+2105.2%) | $10.96 M(-37.6%) |
| June 2011 | - | $137.60 K(-80.1%) | $17.55 M(-32.5%) |
| Mar 2011 | - | $689.80 K(-90.3%) | $26.00 M(+0.9%) |
| Dec 2010 | $25.77 M(+56.3%) | $7.09 M(-26.3%) | $25.77 M(+8.4%) |
| Sept 2010 | - | $9.63 M(+12.2%) | $23.77 M(+26.0%) |
| June 2010 | - | $8.59 M(+1781.5%) | $18.87 M(+22.7%) |
| Mar 2010 | - | $456.30 K(-91.0%) | $15.38 M(-6.7%) |
| Dec 2009 | $16.48 M(+554.9%) | $5.10 M(+7.7%) | $16.48 M(+37.8%) |
| Sept 2009 | - | $4.73 M(-7.0%) | $11.97 M(+49.9%) |
| June 2009 | - | $5.09 M(+225.9%) | $7.98 M(+127.4%) |
| Mar 2009 | - | $1.56 M(+169.1%) | $3.51 M(+39.4%) |
| Dec 2008 | $2.52 M | $580.40 K(-22.5%) | $2.52 M(+9.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2008 | - | $748.70 K(+21.1%) | $2.29 M(+44.8%) |
| June 2008 | - | $618.20 K(+8.5%) | $1.58 M(+35.9%) |
| Mar 2008 | - | $569.60 K(+60.5%) | $1.16 M(+67.6%) |
| Dec 2007 | $694.90 K(>+9900.0%) | $354.90 K(+787.3%) | $694.90 K(+104.4%) |
| Sept 2007 | - | $40.00 K(-80.0%) | $340.00 K(+13.3%) |
| June 2007 | - | $200.00 K(+100.0%) | $300.00 K(+200.0%) |
| Mar 2007 | - | $100.00 K(>+9900.0%) | $100.00 K(>+9900.0%) |
| Dec 2006 | $100.00(-100.0%) | $0.00(0.0%) | $100.00(-100.0%) |
| Sept 2006 | - | $0.00(0.0%) | $1.31 M(-15.9%) |
| June 2006 | - | $0.00(-100.0%) | $1.56 M(-17.0%) |
| Mar 2006 | - | $100.00(-100.0%) | $1.88 M(+0.0%) |
| Dec 2005 | $1.88 M(-14.3%) | $1.31 M(+428.4%) | $1.88 M(+230.6%) |
| Sept 2005 | - | $247.80 K(-22.6%) | $567.80 K(+77.4%) |
| June 2005 | - | $320.00 K(>+9900.0%) | $320.00 K(+1648.6%) |
| Mar 2005 | - | $0.00(0.0%) | $18.30 K(-99.2%) |
| Dec 2004 | $2.19 M(+2420.5%) | $0.00(0.0%) | $2.19 M(0.0%) |
| Sept 2004 | - | $0.00(-100.0%) | $2.19 M(0.0%) |
| June 2004 | - | $18.30 K(-99.2%) | $2.19 M(-3.0%) |
| Mar 2004 | - | $2.17 M(>+9900.0%) | $2.26 M(+2499.4%) |
| Dec 2003 | $86.90 K(-95.1%) | $0.00(0.0%) | $86.90 K(+47.8%) |
| Sept 2003 | - | $0.00(-100.0%) | $58.80 K(-96.8%) |
| June 2003 | - | $86.90 K(>+9900.0%) | $1.85 M(+4.9%) |
| Mar 2003 | - | $0.00(-100.0%) | $1.76 M(0.0%) |
| Dec 2002 | $1.76 M(-50.3%) | -$28.10 K(-101.6%) | $1.76 M(-1.6%) |
| Sept 2002 | - | $1.79 M(>+9900.0%) | $1.79 M(-37.1%) |
| June 2002 | - | $0.00(0.0%) | $2.85 M(-19.3%) |
| Mar 2002 | - | $0.00(0.0%) | $3.53 M(-0.5%) |
| Dec 2001 | $3.55 M(+287.5%) | $0.00(-100.0%) | $3.55 M(-4.2%) |
| Sept 2001 | - | $2.85 M(+317.3%) | $3.71 M(+129.4%) |
| June 2001 | - | $682.90 K(+4038.8%) | $1.62 M(+73.2%) |
| Mar 2001 | - | $16.50 K(-89.4%) | $932.50 K(+1.8%) |
| Dec 2000 | $916.00 K(-87.7%) | $156.20 K(-79.4%) | $916.00 K(+17.4%) |
| Sept 2000 | - | $759.80 K(>+9900.0%) | $780.20 K(+3724.5%) |
| June 2000 | - | $0.00(0.0%) | $20.40 K(-83.1%) |
| Mar 2000 | - | $0.00(-100.0%) | $120.40 K(-98.4%) |
| Dec 1999 | $7.42 M(+1755.1%) | $20.40 K(>+9900.0%) | $7.42 M(+0.3%) |
| Sept 1999 | - | $0.00(-100.0%) | $7.40 M(-1.3%) |
| June 1999 | - | $100.00 K(-98.6%) | $7.50 M(-3.8%) |
| Mar 1999 | - | $7.30 M(+7200.0%) | $7.80 M(+1850.0%) |
| Dec 1998 | $400.00 K(-55.6%) | - | - |
| Sept 1998 | - | $100.00 K(-75.0%) | $400.00 K(-55.6%) |
| June 1998 | - | $400.00 K(-233.3%) | $900.00 K(+80.0%) |
| June 1998 | $900.00 K(-86.6%) | - | - |
| Mar 1998 | - | -$300.00 K(-250.0%) | $500.00 K(-92.9%) |
| Dec 1997 | - | $200.00 K(-66.7%) | $7.00 M(-1.4%) |
| Sept 1997 | - | $600.00 K(>+9900.0%) | $7.10 M(+6.0%) |
| June 1997 | $6.70 M(+509.1%) | $0.00(-100.0%) | $6.70 M(0.0%) |
| Mar 1997 | - | $6.20 M(+1966.7%) | $6.70 M(+1240.0%) |
| Dec 1996 | - | $300.00 K(+50.0%) | $500.00 K(+150.0%) |
| Sept 1996 | - | $200.00 K(>+9900.0%) | $200.00 K(-200.0%) |
| June 1996 | $1.10 M(-650.0%) | - | - |
| Sept 1995 | - | $0.00(0.0%) | -$200.00 K(0.0%) |
| June 1995 | -$200.00 K(-105.1%) | $0.00(-100.0%) | -$200.00 K(0.0%) |
| Mar 1995 | - | -$100.00 K(0.0%) | -$200.00 K(-105.3%) |
| Dec 1994 | - | -$100.00 K(<-9900.0%) | $3.80 M(-2.6%) |
| Sept 1994 | - | $0.00(0.0%) | $3.90 M(0.0%) |
| June 1994 | $3.90 M(-4000.0%) | $0.00(-100.0%) | $3.90 M(0.0%) |
| Mar 1994 | - | $3.90 M(>+9900.0%) | $3.90 M(>+9900.0%) |
| Dec 1993 | - | $0.00(0.0%) | $0.00(0.0%) |
| Sept 1993 | - | $0.00(0.0%) | $0.00(-100.0%) |
| June 1993 | -$100.00 K(-101.9%) | $0.00(0.0%) | -$100.00 K(0.0%) |
| Mar 1993 | - | $0.00(0.0%) | -$100.00 K(0.0%) |
| Dec 1992 | - | $0.00(-100.0%) | -$100.00 K(0.0%) |
| Sept 1992 | - | -$100.00 K | -$100.00 K |
| June 1992 | $5.30 M | - | - |
FAQ
- What is Lineage Cell Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual CFF year-on-year change?
- What is Lineage Cell Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly CFF year-on-year change?
- What is Lineage Cell Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics TTM CFF year-on-year change?
What is Lineage Cell Therapeutics annual cash flow from financing activities?
The current annual CFF of LCTX is $6.42 M
What is the all time high annual CFF for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual cash flow from financing activities is $64.78 M
What is Lineage Cell Therapeutics annual CFF year-on-year change?
Over the past year, LCTX annual cash flow from financing activities has changed by +$4.79 M (+293.57%)
What is Lineage Cell Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of LCTX is -$3000.00
What is the all time high quarterly CFF for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly cash flow from financing activities is $30.97 M
What is Lineage Cell Therapeutics quarterly CFF year-on-year change?
Over the past year, LCTX quarterly cash flow from financing activities has changed by -$810.00 K (-100.37%)
What is Lineage Cell Therapeutics TTM cash flow from financing activities?
The current TTM CFF of LCTX is $14.11 M
What is the all time high TTM CFF for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high TTM cash flow from financing activities is $66.20 M
What is Lineage Cell Therapeutics TTM CFF year-on-year change?
Over the past year, LCTX TTM cash flow from financing activities has changed by +$7.55 M (+115.16%)